摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-dimethylaminomethylene-5-methyl-2-phenyl-2,4-dihydro-pyrazol-3-one | 68538-09-0

中文名称
——
中文别名
——
英文名称
4-dimethylaminomethylene-5-methyl-2-phenyl-2,4-dihydro-pyrazol-3-one
英文别名
(4E)-4-(dimethylaminomethylidene)-5-methyl-2-phenylpyrazol-3-one
4-dimethylaminomethylene-5-methyl-2-phenyl-2,4-dihydro-pyrazol-3-one化学式
CAS
68538-09-0
化学式
C13H15N3O
mdl
——
分子量
229.282
InChiKey
ZKMQJGARZNSQNV-FMIVXFBMSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.7
  • 重原子数:
    17
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.23
  • 拓扑面积:
    35.9
  • 氢给体数:
    0
  • 氢受体数:
    3

文献信息

  • Detection and Treatment of Schizophrenia
    申请人:Itokawa Masanari
    公开号:US20110028470A1
    公开(公告)日:2011-02-03
    The present invention provides a method for diagnosing schizophrenia, and a schizophrenia diagnostic reagent or device for use in the method. The present invention further provides a therapeutic or ameliorating agent for schizophrenia, which is effective for the treatment or amelioration of schizophrenia. The therapeutic or ameliorating agent for schizophrenia contains a carbonyl scavenger or a carbonyl-modified protein formation inhibitor as an active ingredient. The method for diagnosing schizophrenia according to the present invention includes measuring at least one parameter in a subject, the parameter being selected from the group consisting of: (1) a genetic abnormality of glyoxalase I gene; (2) the expression level or activity of glyoxalase I in a biological sample; (3) the amount of a carbonyl compound or a carbonyl-modified protein that is a protein modified with the carbonyl compound; and (4) the amount of pyridoxal in a biological sample.
    本发明提供了一种用于诊断精神分裂症的方法,以及用于该方法的精神分裂症诊断试剂或设备。本发明进一步提供了一种治疗或改善精神分裂症的药剂,该药剂对于治疗或改善精神分裂症有效。用于治疗或改善精神分裂症的药剂包含醛固定剂或醛修饰蛋白形成抑制剂作为活性成分。根据本发明的诊断精神分裂症的方法包括在受试者中测量至少一个参数,所述参数选自以下组合:(1)甘氧化酶I基因的遗传异常;(2)生物样本中甘氧化酶I的表达水平或活性;(3)蛋白质中醛化合物或经醛化合物修饰的蛋白质的量;以及(4)生物样本中吡哆醛的量。
  • Inhibitor of protein modification products formation
    申请人:Miyata Toshio
    公开号:US20070123577A1
    公开(公告)日:2007-05-31
    [PROBLEMS] To provide a inhibitor of protein modification products formation capable of inhibiting of vitamin B6 deficiency disease as a side effect, especially a renal protective agent. [MEANS FOR SOLVING PROBLEMS] There is provided a use, as an active ingredient, of any of free or salt-form compounds of either of the formulae: (I) (II) [wherein R1 is substituted or unsubstituted aromatic ring; and each of R2, R3 and R4 is a hydrogen atom or monovalent organic group, or alternatively R2 and R3 cooperate to form a condensed ring or R3 and R4 cooperate to represent a divalent organic group, provided that R3 and R4 are not simulataneously hydrogen atoms].
    【问题】提供一种蛋白质修饰产物形成的抑制剂,能够抑制维生素B6缺乏病作为副作用,特别是一种肾脏保护剂。 【解决问题的方法】提供一种使用任何自由或盐形式的化合物作为活性成分,其中化合物的公式为(I)或(II): (I)(II) 其中,R1是取代或未取代的芳香环;R2、R3和R4中的每一个是氢原子或一价有机基团,或者R2和R3合作形成一个缩环,或者R3和R4合作表示一个二价有机基团,但要求R3和R4不能同时为氢原子。
  • PROTEIN MODIFIER PRODUCTION INHIBITOR
    申请人:TOKAI UNIVERSITY EDUCATIONAL SYSTEM
    公开号:EP1693369A1
    公开(公告)日:2006-08-23
    [PLOBLEMS] To provide a inhibitor of protein modification products formation capable of inhibiting of vitamin B6 deficiency disease as a side effect, especially a renal protective agent. [MEANS FOR SOLVING PROBLEMS] There is provided a use, as an active ingredient, of any of free or salt-form compounds of either of the formulae: (I) (II) [wherein R1 is substituted or unsubstituted aromatic ring; and each of R2, R3 and R4 is a hydrogen atom or monovalent organic group, or alternatively R2 and R3 cooperate to form a condensed ring or R3 and R4 cooperate to represent a divalent organic group, provided that R3 and R4 are not simulataneously hydrogen atoms].
    [问题] 提供一种能够抑制蛋白质修饰产物形成的抑制剂,作为一种副作用,它能够抑制维 生素 B6 缺乏症,特别是一种肾脏保护剂。[解决问题的方法] 本发明提供了以下式中任何一种游离或盐形式化合物作为活性成分的用途:(I) (II) [其中 R1 是取代或未取代的芳环;R2、R3 和 R4 各为氢原子或一价有机基团,或者 R2 和 R3 配合形成缩合环,或者 R3 和 R4 配合代表二价有机基团,但 R3 和 R4 不能同时为氢原子]。
  • DETECTION AND TREATMENT OF SCHIZOPHRENIA
    申请人:TOKAI UNIVERSITY EDUCATIONAL SYSTEM
    公开号:EP2189537A1
    公开(公告)日:2010-05-26
    The present invention provides a method for diagnosing schizophrenia, and a schizophrenia diagnostic reagent or device for use in the method. The present invention further provides a therapeutic or ameliorating agent for schizophrenia, which is effective for the treatment or amelioration of schizophrenia. The therapeutic or ameliorating agent for schizophrenia contains a carbonyl scavenger or a carbonyl-modified protein formation inhibitor as an active ingredient. The method for diagnosing schizophrenia according to the present invention includes measuring at least one parameter in a subject, the parameter being selected from the group consisting of: (1) a genetic abnormality of glyoxalase I gene; (2) the expression level or activity of glyoxalase I in a biological sample; (3) the amount of a carbonyl compound or a carbonyl-modified protein that is a protein modified with the carbonyl compound; and (4) the amount of pyridoxal in a biological sample.
    本发明提供了一种诊断精神分裂症的方法,以及一种用于该方法的精神分裂症诊断试剂或装置。本发明进一步提供了一种治疗或改善精神分裂症的药剂,该药剂可有效治疗或改善精神分裂症。精神分裂症的治疗剂或改善剂含有羰基清除剂或羰基修饰蛋白形成抑制剂作为活性成分。根据本发明的诊断精神分裂症的方法包括测量受试者体内的至少一个参数,该参数选自由以下组成的组:(1)乙二醛酶I基因的遗传异常;(2)生物样本中乙二醛酶I的表达水平或活性;(3)羰基化合物或羰基修饰蛋白的量,该蛋白是用羰基化合物修饰的蛋白;(4)生物样本中吡哆醛的量。
  • Detection and treatment of schizophrenia
    申请人:TOKAI UNIVERSITY EDUCATIONAL SYSTEM
    公开号:EP2662453A2
    公开(公告)日:2013-11-13
    The present invention relates to a method for diagnosing schizophrenia comprising measuring at least one parameter in a subject, the parameter being selected from the group consisting of (1) a genetic abnormality of glyoxalase I gene, (2) the expression level or activity of glyoxalase I in a biological sample, (3) the amount of a carbonyl-modified protein that is a protein modified with the carbonyl-compound, preferably pentosidine, in a biological sample, and (4) the amount of pyridoxal in a biological sample. The present further relates to a primer, a probe and a reagent for use in said method, as well as an AGE-reader and its use for measuring the amount of carbonyl-modified proteins.
    本发明涉及一种诊断精神分裂症的方法,该方法包括测量受试者体内的至少一个参数,该参数选自以下组别:(1)乙二醛酶 I 基因的遗传异常;(2)生物样本中乙二醛酶 I 的表达水平或活性;(3)生物样本中羰基修饰蛋白质的量,该蛋白质是用羰基化合物(最好是喷托西啶)修饰的蛋白质;(4)生物样本中吡哆醛的量。本发明还涉及一种用于上述方法的引物、探针和试剂,以及一种 AGE 读取器及其在测量羰基修饰蛋白质量时的用途。
查看更多

同类化合物

(4S,4''S)-2,2''-环亚丙基双[4-叔丁基-4,5-二氢恶唑] 香豆素-6-羧酸 锌离子载体IV 钐(III) 离子载体 II 苯,(2,2-二氟乙烯基)- 聚二硫二噻唑烷 缩胆囊肽9 甲酰乙内脲 甲巯咪唑 甲基羟甲基油基噁唑啉 甲基5-羟基-3,5-二甲基-4,5-二氢-1H-吡唑-1-羧酸酯 甲基5-甲基-4,5-二氢-1H-吡唑-1-羧酸酯 甲基5-氰基-4,5-二氢-1,2-恶唑-3-羧酸酯 甲基5-乙炔基-4,5-二氢-1H-吡唑-3-羧酸酯 甲基4-甲基-5-氧代-4,5-二氢-1H-吡唑-3-羧酸酯 甲基4-甲基-4,5-二氢-1H-吡唑-3-羧酸酯 甲基4-乙炔基-4,5-二氢-1H-吡唑-3-羧酸酯 甲基4,5-二氮杂螺[2.4]庚-5-烯-6-羧酸酯 甲基4,5-二氢-5-乙基-1H-吡唑-1-羧酸酯 甲基(E)-3-[6-[1-羟基-1-(4-甲基苯基)-3-(1-吡咯烷基)丙基]-2-吡啶基]丙烯酰酸酯 甲基(5-氧代-4,5-二氢-1,2-恶唑-3-基)乙酸酯 环戊二烯并[d]咪唑-2,5(1H,3H)-二硫酮 溶剂黄93 溴化1-十六烷基-3-甲基咪唑 溴化1-十二烷基-2,3-二甲基咪唑 泰比培南酯中间体 泰比培南酯中间体 氨基甲硫酸,[2-[[(2-羰基-1-咪唑烷基)硫代甲基]氨基]乙基]-,O-甲基酯 异噻唑,4,5-二氯-2,5-二氢-2-辛基- 希诺米啉 四氟硼酸二氢1,3-二(叔-丁基)-4,5--1H-咪唑正离子 四唑硝基紫 噻唑丁炎酮 噻唑,4,5-二氢-4-(1-甲基乙基)-,(S)- 噁唑,4,5-二氢-4,4-二甲基-2-(5-甲基-2-呋喃基)- 噁唑,2-庚基-4,5-二氢- 咪唑烷基脲 吡嗪,2,3-二氢-5,6-二甲基-2-丙基- 叔-丁基3-羟基-1,4,6,7-四氢吡唑并[4,3-c]吡啶-5-羧酸酯 双吡唑啉酮 双[(S)-4-异丙基-4,5-二氢噁唑-2-基]甲烷 双((R)-4-(叔丁基)-4,5-二氢恶唑-2-基)甲烷 利美尼啶D4 利美尼啶 假硫代乙内酰脲 依达拉奉杂质DO 依达拉奉杂质 依达拉奉三聚体 依达拉奉 仲班酸